Amarillo Biosciences Announces Study of Oral Interferon and Tamiflu for Treatment of Influenza AMARILLO, TX–(Marketwire – 12/20/10) – Amarillo Biosciences, Inc. (ABI) (OTC.BB: AMAR – News ) today announced that a clinical trial of ABI’s interferon-alpha lozenges for the treatment of influenza will be launched in Taiwan in 2011. The pilot study, approved by...




